ERBB2 and neoplasm: The rejection of EMT6-mock cells in the CR mice suggests that the tumor rejection was not solely dependent on the exogenous human HER2 antigen (the target of [fam-] trastuzumab deruxtecan) and that the immune system recognized other tumor antigen(s) in EMT6.